Either way, it smells of incompetence with heavy price to pay for us little guys, now that hedgies have bailed out quietly.
Was the complicated titration protocol used more for dose finding? Assuming that case was the case, once the process is nailed down, weren't they right to have recommended an easier titration procedure for real world practice?
At the end of the day, it is all about risk benefit trade off. We have a very favorable risk benefit situation with Tlando that would benefit a lot of patients. If FDA does not approve of this they will be doing a big disservice to the patient community.
Ginridge, that is excellent feedback that the strategy works well. I think in the next couple of weeks the July options activity is going to be very strong!
These are going for 2+ dollars. If you want to hedge, you can sell calls. But you will be regretting big if Tlando gets approval on 28th of this month and stock shoots up big. May be you can sell calls on a part of your position. Good luck!